Vorinostat
- Generic Name
- Vorinostat
- Brand Names
- Zolinza
- Drug Type
- Small Molecule
- Chemical Formula
- C14H20N2O3
- CAS Number
- 149647-78-9
- Unique Ingredient Identifier
- 58IFB293JI
- Background
Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase...
- Indication
用于治疗加重、持续和复发或用两种全身性药物治疗后无效的T细胞淋巴瘤(CTCL, 一种非霍奇金淋巴瘤)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma Recurrent, Persistent Cutaneous T-Cell Lymphoma, Progressive Cutaneous T-cell lymphoma
- Associated Therapies
- -
Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 34
- Registration Number
- NCT01394354
- Locations
- 🇩🇪
University Medical Center Freiburg, Freiburg, Germany
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
- Conditions
High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
- Conditions
- Interventions
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT01378481
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 20
- Registration Number
- NCT01365065
- Locations
- 🇦🇺
The Alfred Hospital - Infectious Diseases Unit, Melbourne, Victoria, Australia
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- University College, London
- Registration Number
- NCT01353482
Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT01342757
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 152
- Registration Number
- NCT01339871
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 25
- Registration Number
- NCT01319383
- Locations
- 🇺🇸
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 2
- Registration Number
- NCT01312818
- Locations
- 🇺🇸
Masonic Cancer Center, University if Minnesota, Minneapolis, Minnesota, United States
High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT01281176
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.